OPEN ACCESS: All This article has a correction
Please see: Half of patients in intensive care receive suboptimal care
- Ray Moynihan
- Sydney
The chief executive officer and chairman of Merck, Raymond Gilmartin, resigned unexpectedly last week, the same day a damning US Congress report on the company was released.
Even though Mr Gilmartin stepped down hurriedly a year ahead of schedule, Merck's official position is that the resignation was not connected to the growing global controversy over its anti-arthritis drug rofecoxib (Vioxx), which was withdrawn from the market late last year, after studies produced evidence …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
PDF
Social bookmarking